A. D. Beadell Investment Counsel Inc. held its stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,507 shares of the medical instruments supplier’s stock at the end of the second quarter. Becton, Dickinson and makes up 2.1% of A. D. Beadell Investment Counsel Inc.’s investment portfolio, making the stock its 11th largest position. A. D. Beadell Investment Counsel Inc.’s holdings in Becton, Dickinson and were worth $2,635,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of BDX. BlackRock Inc. increased its position in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after buying an additional 796,034 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock worth $602,246,000 after buying an additional 39,362 shares in the last quarter. Finally, Fundsmith LLP increased its position in shares of Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock worth $421,291,000 after buying an additional 71,691 shares in the last quarter. 75.57% of the stock is owned by institutional investors and hedge funds.

Shares of Becton, Dickinson and Company (BDX) traded down 0.36% on Friday, reaching $198.60. The company had a trading volume of 494,214 shares. The firm’s 50 day moving average is $199.60 and its 200 day moving average is $188.53. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a market capitalization of $45.19 billion, a PE ratio of 57.52 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the firm earned $2.35 earnings per share. Becton, Dickinson and’s quarterly revenue was down 5.1% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/a-d-beadell-investment-counsel-inc-has-2635000-position-in-becton-dickinson-and-company-bdx/1504659.html.

A number of brokerages have recently issued reports on BDX. Barclays PLC reiterated an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $186.00 to $200.00 in a report on Monday, April 24th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and has an average rating of “Buy” and a consensus price target of $195.79.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Ribo Alberto Mas sold 7,463 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $201.41, for a total value of $1,503,122.83. Following the transaction, the executive vice president now directly owns 29,323 shares in the company, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,631 shares of company stock worth $11,112,178. Corporate insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.